Project description
Microneedle-assisted psoriasis treatment
Psoriasis is a chronic inflammatory skin condition characterised by the rapid buildup of skin cells, leading to the formation of red, itchy patches on the skin. Topical therapy is usually applied but its efficacy is limited due to low skin permeability. Funded by the Marie Skłodowska-Curie Actions programme, the MAPiT project proposes to exploit microneedle array patches (MAPs) to improve skin permeability and avoid the risks associated with systemic drugs for psoriasis. Researchers will load MAPs with nanoparticles containing inhibitors against the tumour necrosis factor (TNF), known for their anti-inflammatory power. The MAPiT approach is expected to lead to higher concentrations of the anti-psoriasis treatment into the skin, improving therapeutic outcome.
Objective
Psoriasis, an autoimmune disorder characterized by keratinocyte hyperproliferation, predominantly manifests as plaque-type psoriasis, with a majority of cases being mild to moderate. Current treatment approaches, such as topical therapy, often fall short due to limited skin permeability. Systemic drugs and biologics, while effective, pose risks associated with high doses. Addressing mild psoriasis presents the challenge of overcoming limited skin permeability and minimizing systemic drug toxicity. Microneedle Array patches (MAPs) offer a promising alternative. They breach the stratum corneum, facilitating intradermal drug delivery, resulting in higher localized drug concentrations compared to systemic or topical administration. Given the pivotal role of TNF-α in psoriasis, I bring expertise in various MAP fabrication techniques, nanomaterials for drug and mRNA delivery, and their applications. By collaborating with the host, we aim to develop an innovative nanomedicine-based strategy. This approach involves encapsulating TNF-α inhibitors in calcium phosphate nanoparticles using flame spray pyrolysis and loading them into MAPs. The research will encompass various parameters, including size, encapsulation efficiency, release kinetics, mechanical strength, morphology, safety, and in vitro efficacy assessment. Beyond the research project, I will engage in personal development courses, gain exposure to state-of-the-art laboratory facilities, and participate in conferences. Additionally, I will mentor Master's and Ph.D. students, honing my project management skills, and collaborate with industry experts and clinicians to explore the formulation's potential.
Fields of science
Keywords
Programme(s)
- HORIZON.1.2 - Marie Skłodowska-Curie Actions (MSCA) Main Programme
Funding Scheme
HORIZON-TMA-MSCA-PF-EF - HORIZON TMA MSCA Postdoctoral Fellowships - European FellowshipsCoordinator
17177 Stockholm
Sweden